Pacira Selling And Marketing Expenses vs Operating Income Analysis

PCRX Stock

USD 29.69 0.63 2.08%

Pacira Pharmaceuticals financial indicator trend analysis is much more than just breaking down Pacira Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Pacira Pharmaceuticals is a good investment. Please check the relationship between Pacira Pharmaceuticals Selling And Marketing Expenses and its Operating Income accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pacira Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Pacira Stock please use our How to Invest in Pacira Pharmaceuticals guide.

Selling And Marketing Expenses vs Operating Income

Selling And Marketing Expenses vs Operating Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Pacira Pharmaceuticals Selling And Marketing Expenses account and Operating Income. At this time, the significance of the direction appears to have strong relationship.

The correlation between Pacira Pharmaceuticals' Selling And Marketing Expenses and Operating Income is 0.79. Overlapping area represents the amount of variation of Selling And Marketing Expenses that can explain the historical movement of Operating Income in the same time period over historical financial statements of Pacira Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Pacira Pharmaceuticals' Selling And Marketing Expenses and Operating Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Selling And Marketing Expenses of Pacira Pharmaceuticals are associated (or correlated) with its Operating Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Operating Income has no effect on the direction of Selling And Marketing Expenses i.e., Pacira Pharmaceuticals' Selling And Marketing Expenses and Operating Income go up and down completely randomly.

Correlation Coefficient

0.79

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Selling And Marketing Expenses

Operating Income

Operating Income is the amount of profit realized from Pacira Pharmaceuticals operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Pacira Pharmaceuticals is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Most indicators from Pacira Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Pacira Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pacira Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Pacira Stock please use our How to Invest in Pacira Pharmaceuticals guide.At this time, Pacira Pharmaceuticals' Tax Provision is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to rise to 0.33 in 2024, whereas Selling General Administrative is likely to drop slightly above 63.1 M in 2024.

	2021	2022	2023	2024 (projected)
Interest Expense	31.8M	40.0M	23.8M	16.1M
Depreciation And Amortization	13.6M	61.4M	75.6M	79.4M

Interest Expense Depreciation And Amortization

Pacira Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross
Total Assets		0.79	0.68	0.96	0.8	0.92	0.22	0.95	0.32	0.58	0.65	0.98	0.84	0.56	0.97	0.78	0.96	0.61	0.65	0.36	0.98	0.94	0.72	0.84	0.92	0.92
Other Current Liab	0.79		0.69	0.68	0.87	0.8	-0.1	0.71	0.12	0.51	0.78	0.76	0.54	0.35	0.8	0.68	0.75	0.58	0.62	0.08	0.8	0.74	0.4	0.74	0.87	0.61
Total Current Liabilities	0.68	0.69		0.51	0.78	0.67	0.11	0.56	0.06	0.12	0.9	0.6	0.82	0.65	0.56	0.79	0.52	0.42	0.45	0.15	0.59	0.55	0.23	0.56	0.81	0.44
Total Stockholder Equity	0.96	0.68	0.51		0.66	0.87	0.22	0.91	0.38	0.6	0.48	0.96	0.76	0.47	0.93	0.66	0.98	0.6	0.66	0.39	0.93	0.96	0.8	0.81	0.79	0.98
Other Liab	0.8	0.87	0.78	0.66		0.77	-0.06	0.67	0.35	0.46	0.87	0.78	0.69	0.39	0.77	0.68	0.72	0.35	0.39	-0.07	0.79	0.69	0.43	0.61	0.88	0.62
Property Plant And Equipment Net	0.92	0.8	0.67	0.87	0.77		0.29	0.91	0.16	0.63	0.6	0.88	0.8	0.67	0.89	0.82	0.85	0.73	0.76	0.47	0.9	0.86	0.6	0.93	0.94	0.79
Current Deferred Revenue	0.22	-0.1	0.11	0.22	-0.06	0.29		0.28	-0.34	0.35	0.0	0.11	0.29	0.36	0.24	0.5	0.14	0.3	0.27	0.7	0.23	0.19	0.08	0.38	0.23	0.15
Net Debt	0.95	0.71	0.56	0.91	0.67	0.91	0.28		0.3	0.61	0.45	0.94	0.78	0.63	0.96	0.72	0.9	0.57	0.6	0.45	0.96	0.85	0.67	0.81	0.88	0.86
Retained Earnings	0.32	0.12	0.06	0.38	0.35	0.16	-0.34	0.3		0.04	0.08	0.46	0.34	0.16	0.29	-0.16	0.37	-0.34	-0.32	-0.42	0.31	0.25	0.4	-0.13	0.18	0.42
Accounts Payable	0.58	0.51	0.12	0.6	0.46	0.63	0.35	0.61	0.04		0.19	0.55	0.28	0.2	0.67	0.52	0.6	0.34	0.41	0.5	0.65	0.62	0.3	0.67	0.54	0.55
Cash	0.65	0.78	0.9	0.48	0.87	0.6	0.0	0.45	0.08	0.19		0.57	0.66	0.37	0.56	0.73	0.52	0.39	0.42	-0.05	0.59	0.55	0.29	0.52	0.78	0.43
Non Current Assets Total	0.98	0.76	0.6	0.96	0.78	0.88	0.11	0.94	0.46	0.55	0.57		0.78	0.5	0.96	0.65	0.98	0.53	0.58	0.23	0.97	0.93	0.76	0.76	0.87	0.94
Non Currrent Assets Other	0.84	0.54	0.82	0.76	0.69	0.8	0.29	0.78	0.34	0.28	0.66	0.78		0.81	0.72	0.8	0.71	0.44	0.46	0.39	0.75	0.69	0.55	0.65	0.83	0.72
Other Assets	0.56	0.35	0.65	0.47	0.39	0.67	0.36	0.63	0.16	0.2	0.37	0.5	0.81		0.48	0.68	0.38	0.34	0.34	0.56	0.51	0.39	0.22	0.53	0.66	0.35
Long Term Debt	0.97	0.8	0.56	0.93	0.77	0.89	0.24	0.96	0.29	0.67	0.56	0.96	0.72	0.48		0.74	0.94	0.58	0.61	0.34	1.0	0.89	0.71	0.82	0.9	0.88
Cash And Short Term Investments	0.78	0.68	0.79	0.66	0.68	0.82	0.5	0.72	-0.16	0.52	0.73	0.65	0.8	0.68	0.74		0.63	0.64	0.65	0.62	0.75	0.67	0.36	0.83	0.87	0.57
Net Receivables	0.96	0.75	0.52	0.98	0.72	0.85	0.14	0.9	0.37	0.6	0.52	0.98	0.71	0.38	0.94	0.63		0.59	0.66	0.28	0.95	0.97	0.78	0.79	0.81	0.97
Common Stock Total Equity	0.61	0.58	0.42	0.6	0.35	0.73	0.3	0.57	-0.34	0.34	0.39	0.53	0.44	0.34	0.58	0.64	0.59		0.98	0.55	0.57	0.65	0.5	0.88	0.61	0.56
Common Stock Shares Outstanding	0.65	0.62	0.45	0.66	0.39	0.76	0.27	0.6	-0.32	0.41	0.42	0.58	0.46	0.34	0.61	0.65	0.66	0.98		0.55	0.6	0.74	0.53	0.9	0.63	0.62
Short Term Investments	0.36	0.08	0.15	0.39	-0.07	0.47	0.7	0.45	-0.42	0.5	-0.05	0.23	0.39	0.56	0.34	0.62	0.28	0.55	0.55		0.33	0.35	0.15	0.63	0.32	0.3
Non Current Liabilities Total	0.98	0.8	0.59	0.93	0.79	0.9	0.23	0.96	0.31	0.65	0.59	0.97	0.75	0.51	1.0	0.75	0.95	0.57	0.6	0.33		0.9	0.71	0.82	0.91	0.89
Inventory	0.94	0.74	0.55	0.96	0.69	0.86	0.19	0.85	0.25	0.62	0.55	0.93	0.69	0.39	0.89	0.67	0.97	0.65	0.74	0.35	0.9		0.75	0.84	0.79	0.95
Other Current Assets	0.72	0.4	0.23	0.8	0.43	0.6	0.08	0.67	0.4	0.3	0.29	0.76	0.55	0.22	0.71	0.36	0.78	0.5	0.53	0.15	0.71	0.75		0.56	0.52	0.83
Other Stockholder Equity	0.84	0.74	0.56	0.81	0.61	0.93	0.38	0.81	-0.13	0.67	0.52	0.76	0.65	0.53	0.82	0.83	0.79	0.88	0.9	0.63	0.82	0.84	0.56		0.84	0.74
Total Liab	0.92	0.87	0.81	0.79	0.88	0.94	0.23	0.88	0.18	0.54	0.78	0.87	0.83	0.66	0.9	0.87	0.81	0.61	0.63	0.32	0.91	0.79	0.52	0.84		0.71
Property Plant And Equipment Gross	0.92	0.61	0.44	0.98	0.62	0.79	0.15	0.86	0.42	0.55	0.43	0.94	0.72	0.35	0.88	0.57	0.97	0.56	0.62	0.3	0.89	0.95	0.83	0.74	0.71

Click cells to compare fundamentals

Pacira Pharmaceuticals Account Relationship Matchups

Pacira Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	831.1M	1.3B	2.1B	1.7B	1.6B	1.7B
Other Current Liab	18.2M	14.7M	117.9M	89.8M	64.2M	36.3M
Total Current Liabilities	107.7M	253.3M	521.1M	147.8M	97.4M	123.5M
Total Stockholder Equity	354.9M	619.7M	730.4M	775.0M	870.1M	913.6M
Other Liab	21.5M	17.4M	77.6M	37.8M	43.5M	24.9M
Property Plant And Equipment Net	142.8M	211.2M	264.8M	254.4M	234.9M	120.3M
Net Debt	273.7M	441.2M	543.3M	659.3M	432.7M	454.4M
Retained Earnings	(399.4M)	(253.9M)	(211.9M)	(148.8M)	(106.8M)	(112.1M)
Accounts Payable	12.8M	10.4M	10.5M	15.2M	15.7M	10.4M
Cash	78.2M	100.0M	585.6M	104.1M	153.3M	117.4M
Non Current Assets Total	422.5M	622.9M	1.2B	1.2B	1.1B	1.1B
Non Currrent Assets Other	11.0M	74.5M	76.4M	27.2M	36.0M	37.9M
Other Assets	971K	290.1M	153.4M	160.3M	1.0	0.95
Long Term Debt	306.0M	313.0M	674.5M	655.8M	513.8M	539.5M
Cash And Short Term Investments	292.0M	521.7M	656.4M	288.7M	278.6M	237.8M
Net Receivables	47.5M	53.0M	96.3M	98.4M	105.6M	110.8M
Common Stock Shares Outstanding	41.5M	43.7M	45.6M	46.5M	52.0M	35.9M
Short Term Investments	213.7M	421.7M	70.8M	184.5M	125.3M	137.9M
Liabilities And Stockholders Equity	831.1M	1.3B	2.1B	1.7B	1.6B	1.7B
Non Current Liabilities Total	368.4M	401.5M	823.8M	758.4M	606.9M	637.2M
Inventory	58.3M	64.7M	98.6M	96.1M	104.4M	109.6M
Other Current Assets	10.8M	12.3M	14.8M	15.2M	21.5M	22.6M
Other Stockholder Equity	754.0M	873.2M	942.1M	924.1M	976.6M	599.8M
Total Liab	476.1M	654.8M	1.3B	906.2M	704.3M	396.5M
Property Plant And Equipment Gross	142.8M	211.2M	264.8M	254.4M	370.3M	388.8M
Total Current Assets	408.6M	651.6M	866.0M	498.3M	510.0M	331.8M
Accumulated Other Comprehensive Income	322K	318K	167K	(380K)	247K	259.4K
Short Term Debt	4.9M	157.1M	382.6M	42.8M	17.4M	16.6M
Common Stock	42K	44K	45K	46K	52.9K	35.1K
Property Plant Equipment	104.7M	136.7M	264.8M	254.4M	292.5M	307.2M
Short Long Term Debt Total	351.9M	541.1M	1.1B	763.4M	586.0M	348.5M
Net Tangible Assets	151.0M	423.6M	(38.7M)	71.2M	81.9M	77.8M
Retained Earnings Total Equity	(388.2M)	(399.4M)	(253.9M)	(211.9M)	(190.7M)	(200.2M)
Long Term Debt Total	276.2M	290.6M	306.0M	313.0M	360.0M	240.7M
Capital Surpluse	709.7M	754.0M	873.2M	942.1M	1.1B	685.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

OEPIX	Oil Equipment Services
MMM	3M Company
SLV	iShares Silver Trust

When determining whether Pacira Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Pacira Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pacira Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pacira Pharmaceuticals Stock:

How To Invest In Pacira

Details

Is Pacira Stock a good investment?

Details

What is Pacira Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pacira Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Pacira Stock please use our How to Invest in Pacira Pharmaceuticals guide.

You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.

Complementary Tools for Pacira Stock analysis

When running Pacira Pharmaceuticals' price analysis, check to measure Pacira Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira Pharmaceuticals is operating at the current time. Most of Pacira Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pacira Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pacira Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios
	Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk
	Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
	Insider Screener Find insiders across different sectors to evaluate their impact on performance
	Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators
	Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios.
	Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets
	Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
	My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
	Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities
	Fundamental Analysis View fundamental data based on most recent published financial statements

Is Pacira Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pacira Pharmaceuticals. If investors know Pacira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pacira Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.291

Earnings Share

1.51

Revenue Per Share

14.706

Quarterly Revenue Growth

0.042

Return On Assets

0.0376

The market value of Pacira Pharmaceuticals is measured differently than its book value, which is the value of Pacira that is recorded on the company's balance sheet. Investors also form their own opinion of Pacira Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Pacira Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pacira Pharmaceuticals' market value can be influenced by many factors that don't directly affect Pacira Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Pacira Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pacira Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pacira Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Pacira Selling And Marketing Expenses vs Operating Income Analysis

Selling And Marketing Expenses vs Operating Income

Selling And Marketing Expenses vs Operating Income Correlation Analysis

Correlation Coefficient

Selling And Marketing Expenses

Operating Income

Pacira Pharmaceuticals fundamental ratios Correlations

Pacira Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Pacira Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

Complementary Tools for Pacira Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Liabilities Total	+ 1.0	Long Term Debt
Non Current Assets Total	+ 0.98	Total Assets
Non Current Liabilities Total	+ 0.98	Total Assets
Net Receivables	+ 0.98	Total Stockholder Equity
Property Plant And Equipment Gross	+ 0.98	Total Stockholder Equity
Net Receivables	+ 0.98	Non Current Assets Total

Short Term Investments	- 0.42	Retained Earnings
Common Stock Total Equity	- 0.34	Retained Earnings
Retained Earnings	- 0.34	Current Deferred Revenue
Common Stock Shares Outstanding	- 0.32	Retained Earnings
Cash And Short Term Investments	- 0.16	Retained Earnings
Other Stockholder Equity	- 0.13	Retained Earnings